Next-generation CAR-T
Evaluate assets with initial research data, defined rights and practical technology-transfer potential. The lead indication and product design remain subject to scientific selection.
EVOKEA BIO / CELL & GENE THERAPYAwakening
Awakening
the possibilities
of living science.
Connecting promising science, specialist expertise and purposeful collaboration to advance cell and gene therapy development.
CELL & GENE THERAPY
A PATIENT-LED PERSPECTIVEEvidence before expansionFocused developmentConnected expertise
OUR DIRECTIONSmall beginnings.
Small beginnings.
Meaningful possibilities.
A focused path from scientific potential to a defined therapeutic product.
Evokea Bio is a biotechnology venture in formation. We plan to build a US-based development organization through technology acquisition, specialist teams and one focused lead program.
Meet EvokeaTHE SCIENTIFIC FOCUSLiving systems.
Our scientific approachLiving systems.
Considered possibilities.
Ex vivo gene editing
Compare gene-edited cell therapy approaches where they can address a defined product need. Editing is a potential tool within a cell therapy, rather than a separate promise of efficacy.
One focused lead program
Concentrate early resources on one lead development program, with limited alternatives that address identified risks and share an evaluation framework.
A CONNECTED DEVELOPMENT PATH
Explore the pathwayProgress, guided by evidence.
Clinical need & technology review
Understand the target patient, examine available evidence and clarify rights before selecting a lead program.
Key results & candidate definition
Review core findings and evaluate whether the candidate has a credible scientific and manufacturing path.
Process, analytics & quality
Integrate nonclinical research, process development and controlled quality records into one development plan.
Regulatory & clinical readiness
Progress only when the product evidence, manufacturing, regulatory and clinical conditions are in place.